Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities (ASPIRE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to increase treatment of acute stroke with tissue plasminogen activator (tPA) across the District of Columbia. This study, however, will not evaluate tPA as an intervention.
| Condition |
|---|
|
Stroke |
| Study Type: | Observational |
| Study Design: | Observational Model: Ecologic or Community Time Perspective: Prospective |
| Official Title: | Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities |
- The proportion of people with ischemic stroke appropriately treated with IV tPA. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
- Qualitative data collected from the community will identify baseline levels of knowledge, attitudes, and perceived and encountered barriers to acute stroke treatment. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 2005 |
| Study Start Date: | February 2008 |
| Estimated Study Completion Date: | January 2013 |
| Estimated Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Adults living in DC neighborhoods with high proportions of underserved adults. The age of the cohort members will reflect the age of DC residents who suffer most from stroke.
|
Detailed Description:
There are a number of well-known barriers to receiving tissue plasminogen activator (tPA) including transit time to hospital, paramedic and provider training, tPA standing orders, and provider guidelines. Among underserved populations, limited stroke knowledge, socioculturally determined attitudes, and beliefs and myths held by community members may serve as additional barriers that hinder these populations from receiving tPA and acute stroke care. Targeted multilevel interventions designed to overcome specific barriers may significantly increase the number of individuals with stroke who are appropriately treated with intravenous tPA (IV tPA) in underserved communities. Identification of the specific components of healthcare interventions that are the most effective is critical to improve delivery of acute stroke therapy.
The goal of this study is to learn more about public knowledge, attitudes, beliefs and perceptions regarding stroke and stroke treatment in order to identify sociocultural and environmental barriers to receiving tPA and acute stroke care in an underserved community. This study will also determine if implementation of a multilevel intervention program can significantly increase the number of people with ischemic stroke who are appropriately treated with IV tPA in a predominantly underserved community.
In the study, researchers will evaluate the different levels of the intervention to determine which efforts are most effective.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Adult residents of the District of Columbia
Inclusion Criteria:
- diagnosis of acute ischemic stroke
- over the age of 18
Exclusion Criteria:
-
Contacts and Locations| United States, District of Columbia | |
| Georgetown University, ASPIRE Coordinating Center | |
| Washington, District of Columbia, United States, 20007 | |
| Sibley Memorial Hospital | |
| Washington, District of Columbia, United States, 20016 | |
| Providence Hospital | |
| Washington, District of Columbia, United States, 20017 | |
| Washington Hospital Center | |
| Washington, District of Columbia, United States, 20010 | |
| United Medical Center (formerly known as Greater Southeast Community Hospital) | |
| Washington, District of Columbia, United States, 20032 | |
| Howard University Hospital | |
| Washington, District of Columbia, United States, 20060 | |
| George Washington University Hospital | |
| Washington, District of Columbia, United States, 20037 | |
| United States, New York | |
| Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| Principal Investigator: | Chelsea Kidwell, MD | Georgetown University |
More Information
No publications provided
| Responsible Party: | Chelsea Kidwell, M.D., Professor of Neurology and Medical Director, Georgetown University Stroke Center, Georgetown University |
| ClinicalTrials.gov Identifier: | NCT00724555 History of Changes |
| Other Study ID Numbers: | U54NS057405_ASPIRE, 2007-439 |
| Study First Received: | July 28, 2008 |
| Last Updated: | December 10, 2012 |
| Health Authority: | United States: Federal Government United States: Georgetown University Institutional Review Board |
Keywords provided by Georgetown University:
|
stroke tissue plasminogen activator tPA |
Additional relevant MeSH terms:
|
Stroke Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Brain Infarction |
Brain Ischemia Tissue Plasminogen Activator Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Cardiovascular Agents Therapeutic Uses Hematologic Agents |
ClinicalTrials.gov processed this record on May 23, 2013